Biochemistry/Molecular Biology - ARVO

ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - Biochemistry/Molecular BiologyLaila A A. Eissa, None; Mamdouh El-Shishtawy, None; GregoryI. Liou, NoneSupport: Egyptian Cultural and Educational Bureau (NME andGIL), Department of Defense DM102155 (GIL) and VisionDiscovery Institute (GIL)Program Number: 1156 Poster Board Number: D0060Presentation Time: 1:00 PM - 2:45 PMPeripheral Retinal Perfusion and Functional Analysis of Patientswith Ischemic Central Retinal Vein OcclusionCharles Wykoff 1, 2 , David M. Brown 1, 2 , Daniel Croft 1 . 1 RetinaConsultants of Houston, Houston, TX; 2 Weill Cornell MedicalCollege, Methodist Hospital, Houston, TX.Purpose: Progressive retinal perfusion and peripheral visual field(VF) changes in eyes with central retinal vein occlusions (CRVO) areincompletely understood. Our purpose was to quantify long-termtrends in capillary non-perfusion and VF patterns in patients withischemic CRVO treated with ranibizumab over 36 months.Methods: Wide-field fluorescein angiography (FA) and GoldmannVF (GVF) were performed serially in patients with ischemic CRVOwho were treated in the 36-month prospective Rubeosis Anti-VEGF(RAVE) trial evaluating intravitreal ranibizumab. All patientsreceived ranibizumab injections for 9 months followed by pro re nataranibizumab in months 12-36. Serial wide-field FA was performedwith a Heidelberg Spectralis HRA utilizing the Staurenghi contactlens. Areas of perfusion/non-perfusion were graded by maskedgraders and pixels quantified. GVF were assessed every 6 monthsand changes in the I-4e isopter were analyzed.Results: Twelve patients had sequential wide-field FA for 36months. At baseline, mean perfusion was 36.7% (106.4 disc areas) ofthe gradable field (mean: 290 disc areas, range 178-452). The area ofnon-perfusion increased in all patients with a mean loss ofapproximately 5% of retina area (loss of 14.5 mean disc areas ofperfusion) per 6 month period. In comparison to progressive loss ofperfusion, 3 patterns of GVF progression were identified: early loss(n=6), early gain with late loss (n=3), and stability (n=3). Progressivenon-perfusion and changes in GVF were most pronounced in the firstyear of the trial. Despite capillary and GVF losses, vision improvedin these eyes from a baseline of 23.1 best corrected Early TreatmentDiabetic Retinopathy Study (ETDRS) letters to 30.5 ETDRS letters(mean gain: +7.4 letters) at month 36.Conclusions: In this prospective CRVO trial, progressive capillaryloss was quantified. Similarly, peripheral visual field loss asmeasured by GVF progressed in most eyes (n=9). Changes inperfusion and GVF were particularly evident in the first year oftreatment. Despite perfusion and GVF losses in many patients, visionimproved, as the majority of these anatomic and functional changeswere peripheral.Wide field fluorescein angiogram of ischemic CRVO at baselineWide field fluorescein angiogram of the same ischemic CRVO after 2years of intravitreal ranibizumab treatment showing extensive loss ofretinal perfusionCommercial Relationships: Charles Wykoff, Genentech (R),Regeneron (R), Bayer (C); David M. Brown, RegeneronPharmaceuticals, Inc. (F), Regeneron Pharmaceuticals, Inc. (C),Regeneron Pharmaceuticals, Inc. (R), Bayer HealthCare (F), BayerHealthCare (C), Bayer HealthCare (R), Genentech (C), Roche (C),Alimera (C), Alcon (C), Novartis (C), Thrombogenics (C),Genentech (F), Roche (F), Thrombogenics (F), GSK (F), Alimera (F),Alcon (F), Allergan (F), Eli Lilly (F); Daniel Croft, NoneClinical Trial: NCT00406471Program Number: 1157 Poster Board Number: D0061Presentation Time: 1:00 PM - 2:45 PMThe Aqueous Humor Proteome in Patients with DiabeticRetinopathyRachida Bouhenni 1 , Deepak P. Edward 2, 3 , Sandeep Grover 4 , KakarlaChalam 4 , Abby L. Sewell 1 , Khaled K. Abu-Amero 5 . 1 Ophthalmology,Summa Health System, Akron, OH; 2 Ophthalmology, King KhaledEye Research Hospital, Riyadh, Saudi Arabia; 3 Ophthalmology,Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD;4 Ophthalmology, University of Florida, Jacksonville, FL; 5 Genetics,King Saud University, Riyadh, Saudi Arabia.©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the ARVO Office at arvo@arvo.org.